Tumor suppressor and anti-inflammatory protein: an expanded view on   insulin-degrading enzyme (IDE)
  In 1994, I conjectured that insulin-degrading enzyme (IDE) acts as an inhibitor of malignant transformation by degrading insulin and thus preventing this major growth-stimulatory hormone from binding and thereby inactivating the retinoblastoma tumor suppressor protein (RB). Ten years later, I discovered that a carboxyterminal RB amino acid sequence resembles the catalytic center of IDE. This structural homology raised the possibility that insulin degradation is a basic mechanism for tumor suppression shared by RB and IDE. Subsequently, a first immunohistochemical study on the differential expression of human IDE in normal tissues, primary tumors and their corresponding lymph node metastases further corroborated the initial conjecture on IDE being an antineoplastic molecule. In this report, it is shown that IDE harbors ankyrin repeat-like amino acid sequences through which it might bind and, as a result, antagonize the pro-inflammatory factor NF-kappaB as well as cyclin-dependent kinases (CDKs). As equally revealed here, IDE also contains 2 RXL cyclin-binding motifs which could contribute to its presumed inhibition of CDKs. These new findings suggest that IDE is potentially able to suppress both inflammation and oncogenesis by several mechanisms that ultimately ensure RB function. 
Razvan Tudor Radulescu